Richard Lowenthal

And that's why what you see as the wholesale price and we can talk about this.

A little bit, I think you have other questions you're going to ask about this, but what you see as the wholesale price as a manufacturer, the developer of this product and put in all the research and development money and our investors and also as the manufacturer, we get roughly 50% of that price.

So, when we take into account the PBM costs, the rebates back to payers, the distribution costs and the retail pharmacy costs and our copay assistance program, we retain about 50% of the actual published price of the product.

Yeah, so in our pricing strategy, we try to work very hard to protect the consumer and the patient.

So the patient caregiver, I say, is consumer, right?

Because in large number, it's the caregiver making the decision to buy or which epinephrine product they want to buy.

So we...

Mainly focused on them, so that there's no price barrier to switch to.

Of course, if they're insurers is insurance is not covering yet or or they're denied on a prior authorization.

Of course, there's some price barrier in that regard, but I'll talk about that in a minute.

But we focused in that regard to keep that copay as low as possible.

We started off with a 25 dollar copay, but we've now lowered it to 0.

So that copay should be zero for any commercially insured person who gets coverage and doesn't have very high deductibles.

And the reason we...

Focused on that is that that that is the decision maker and getting the product.

We think this is a very consumer oriented type of product.

It's.

The allergist practice shared decision making.

So, if if a patient has a strong preference for 1 epinephrine product over another.

The allergist will generally prescribe that because again, their main focus is that you're willing to carry it and use it.